2023-06-29 07:02:17 ET
- Rite Aid press release ( NYSE: RAD ): Q1 Non-GAAP EPS of -$0.73 beats by $0.84 .
- Net Loss of $306.7 Million Compared to Prior Year Net Loss of $110.2 Million – Increase Largely Attributable to a Goodwill Impairment Charge at Elixir
- Revenue of $5.65B (-6.0% Y/Y) beats by $420M .
- Retail Comparable Same Store Prescriptions Increased 4.7 Percent – Comparable Same Store Prescriptions, Excluding COVID Impact, Increased 7.4 Percent
- FY23 outlook:
-
Total revenues are expected to be between $22.6 billion and $23.0 billion in fiscal 2024. Retail Pharmacy Segment revenue is expected to be between $18.0 billion and $18.3 billion, and Pharmacy Services Segment revenue is expected to be between $4.6 billion and $4.7 billion, net of any intercompany revenues to the Retail Pharmacy Segment.
Net loss is expected to be between approximately $650 million and $680 million.
Adjusted net loss per share is expected to be between $4.29 and $4.78.
Capital expenditures are now expected to be approximately $175 million, with a focus on investments in technology, prescription file purchases and distribution center automation.
For further details see:
Rite Aid Non-GAAP EPS of -$0.73 beats by $0.84, revenue of $5.65B beats by $420M